Opus Genetics Inc. (IRD) posted a net loss of $0.80 per share for fiscal 2025. The company generated $14.2M in revenue for the year. The clinical-stage ophthalmic biopharmaceutical company focuses on developing therapies for inherited retinal diseases.
Opus Genetics is advancing OPGx-LCA5, currently in Phase 1/2 clinical trial for LCA5-associated IRD, and OPGx-BEST1 for BEST1-associated retinal disease. The company operates in the specialized sector of rare genetic eye disorders.
A detailed analysis of Opus Genetics Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Opus Genetics Inc. (IRD) Reports FY25 Earnings first appeared on Alphastreet.
